BioCardia (BCDA) Stock Price, News & Analysis

Company Overview

BioCardia, Inc. is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System. The Helix system is designed to facilitate precise, minimally invasive delivery of cells and biologics into viable myocardium. CardiAMP is an autologous bone marrow-derived progenitor cell therapy under investigation for its potential to improve cardiac function in patients with ischemic heart failure. Both platforms have secured investigational device exemptions from the U.S. Food and Drug Administration and are being evaluated in multi-center clinical trials.

Founded in the mid-2000s and headquartered in the San Francisco Bay Area, BioCardia has assembled a leadership team with deep expertise in interventional cardiology, regenerative medicine, and medical device development. Gary S. Margulies, M.D., serves as President and Chief Executive Officer, guiding the company’s clinical programs and strategic partnerships. BioCardia collaborates with academic medical centers and clinical research organizations across the United States to advance its pipeline and ultimately bring new therapeutic options to patients suffering from heart disease.

Key Stats

• Today's Range: $1.10 to $1.16
• 50-Day Range: $1.10 to $1.35
• 52-Week Range: $1.00 to $2.92
• Volume: 94,208 shs
• Average Volume: 62,303 shs
• Market Capitalization: $12.03 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.00
• Consensus Rating: Hold

BioCardia Stock Analysis - MarketRank™

BioCardia scored higher than 70% of companies evaluated by MarketBeat, and ranked 201st out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

BioCardia has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

BioCardia has a consensus price target of $25.00, representing about 2,172.7% upside from its current price of $1.10.

Amount of Analyst Coverage

BioCardia has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BioCardia are expected to grow in the coming year, from ($0.71) to ($0.56) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BioCardia is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioCardia is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BioCardia has a P/B Ratio of 13.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.95% of the float of BioCardia has been sold short.

Short Interest Ratio / Days to Cover

BioCardia has a short interest ratio ("days to cover") of 2.78, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioCardia has recently decreased by 0.44%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioCardia does not currently pay a dividend.

Dividend Growth

BioCardia does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: N/A

News Sentiment

BioCardia has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for BioCardia this week, compared to 3 articles on an average week.

Search Interest

3 people have searched for BCDA on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

7 people have added BioCardia to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days.

Company Ownership

• Score: 3.7 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $6,780.00 in company stock, which represents 0.0563% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, BioCardia insiders have bought more of their company's stock than they have sold. Specifically, they have bought $6,780.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

17.40% of the stock of BioCardia is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

20.57% of the stock of BioCardia is held by institutions.

BCDA Stock Analysis - Frequently Asked Questions

How have BCDA shares performed this year?

BioCardia's stock was trading at $1.25 at the start of the year. Since then, BCDA shares have decreased by 12.0% and is now trading at $1.10.

How were BioCardia's earnings last quarter?

BioCardia, Inc. (NASDAQ:BCDA) issued its quarterly earnings data on Tuesday, March, 24th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.14.
Read the conference call transcript.

When did BioCardia's stock split?

Shares of BioCardia reverse split before market open on Thursday, May 30th 2024.The 1-15 reverse split was announced on Thursday, May 30th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did BioCardia IPO?

BioCardia (BCDA) raised $51 million in an IPO on the week of July 20th 2015. The company issued 3,900,000 shares at $12.00-$14.00 per share. Cantor Fitzgerald & Co. served as the underwriter for the IPO and Roth Capital Partners and Maxim Group were co-managers.

How do I buy shares of BioCardia?

Shares of BCDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BioCardia own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioCardia investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), Predictive Oncology (POAI), Abbott Laboratories (ABT), Ford Motor (F) and Wells Fargo & Company (WFC).

Company Calendar

• Last Earnings: 3/24/2026
• Today: 5/05/2026
• Next Earnings (Estimated): 5/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BCDA
• CIK: 925741
• Web: www.biocardia.com
• Phone: (650) 226-0120
• Fax: 310-861-5299
• Employees: 40
• Year Founded: 2002

Price Target and Rating

• Average Price Target for BioCardia: $25.00
• High Price Target: $25.00
• Low Price Target: $25.00
• Potential Upside/Downside: +2,172.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.29)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.23 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -28,372.40%
• Return on Assets: -238.22%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.12
• Quick Ratio: 1.12

Sales & Book Value

• Annual Sales: $60 thousand
• Price / Sales: 200.57
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.08 per share
• Price / Book: 13.75

Miscellaneous

• Outstanding Shares: 10,940,000
• Free Float: 9,036,000
• Market Cap: $12.03 million
• Optionable: Optionable
• Beta: 0.56